2 assets in Hypopharynx Squamous Cell Carcinoma

Therapeutic assets addressing Hypopharynx Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Hypopharynx Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Hypopharynx Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)